Abstract
This study was carried out to evaluate sustained release diclofenac sodium matrix tablets formulated using Brachystegia eurycoma gum (BEG) as matrix polymer. BEG was isolated by acetone -precipitation of the filtrate obtained from the maceration of powdered dried seeds of Brachystegia eurycoma in distilled water. Diclofenac sodium matrix tablets were produced by non-aqueous wet granulation method using BEG as the hydrophilic matrix former. The tablets were evaluated using official and unofficial tests such as; uniformity of weight, content uniformity, dissolution test, tablets diameter, thickness, hardness and friability tests. The drug release profile of the matrix tablets were compared to that formulated using a standard matrix former, hydroxypropylmethylcellulose (HPMC). Hardness values ranged from 6.12 ± 1.80 to 9.73 ± 1.39 kgf, friability from 0.31 ± 0.00 to 1.00 ± 0.00%. The drug content ranged from 98 to 101 %. The percentage drug released from the matrix tablets after 10 h was between 71.27 and 98.73 % except for formulation BF3 that released 32.56 %. This study showed that sustained release diclofenac sodium matrix tablets were successfully formulated using Brachystegia eurycoma gum as the matrix former and the tablets were comparable to that formulated with HPMC.
 Keywords: Brachystegia eurycoma gum; Diclofenac sodium; Matrix tablets; Sustained release
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
